Advanced Gastroesophageal Cancer
Publication Date: January 4, 2023
Key Points
Key Points
- Gastroesophageal cancers are among the most prevalent gastrointestinal malignancies worldwide. In 2020, there were over 1 million new cases and 769,000 deaths due to gastric cancer.
- Most gastric and gastrointestinal junction tumors are adenocarcinoma.
- Targeted cancer therapies and immunotherapy are more effective in subgroups of gastroesophageal cancer patients who possess certain biomarkers such as programmed death-ligand 1 (PD-L1) protein expression.
Treatment
...reatment
Figure 1. Immunotherapy and Targeted Th...
...-line Therapy...
...ndation 1.1For HER2-negative patients...
...tion 1.2For HER2-negative patients with esoph...
...1.3For patients with ESCC and PD-L1 CPS â...
...ecommendation 1.4For patients with...
...ion 1.5For patients with HER2-positive gas...
...r Third-line Therapy...
...2.1For patients with advanced gastroesophageal or...
...2.2For HER2-positive patients with gastric or...